Wells Fargo & Company MN Sells 21,533 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wells Fargo & Company MN lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 152,508 shares of the biopharmaceutical company’s stock after selling 21,533 shares during the quarter. Wells Fargo & Company MN’s holdings in Regeneron Pharmaceuticals were worth $108,636,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in REGN. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $802,036,000. Amundi raised its stake in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the period. Loomis Sayles & Co. L P lifted its holdings in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.1 %

REGN stock opened at $572.78 on Tuesday. The firm has a 50-day moving average price of $674.46 and a 200-day moving average price of $772.53. Regeneron Pharmaceuticals, Inc. has a 12 month low of $557.83 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $62.62 billion, a P/E ratio of 14.96, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Robert W. Baird reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.